For years, Geron has bragged that “next year” it would be permitted to conduct human ESCR trials on people with newly acquired spinal cord injuries. And for years, that promise has been like the check in the mail that never comes. Finally, this summer, Geron was permitted to begin. But now, the FDA has backed off again, delaying the trials again. From the story:
Regulators are delaying a trial of an embryonic stem cell treatment for spinal cord injury, drug developer Geron Corp. said Tuesday. Geron said the Food and Drug Administration is reviewing new data from studies of the therapy, called GRNOPC1, on animals. The company plans to start testing its product on humans this summer, but that testing will be delayed during the FDA’s review. Geron said it will work with the FDA, and did not estimate how long the review will take.
Better safe than very sorry, given the risk of tumors. Indeed, I have spoken with enthusiastic ESCR proponents who are very worried that human testing is premature. In any event, once again there are no approved human trials for embryonic stem cell research as the adult sector continues its surge forward.
YOU MIGHT ALSO LIKE
Ethics of Rhetoric in Times of War
What we say matters. And the way we say it matters. This is especially true in times…
How the State Failed Noelia Castillo
On March 26, Noelia Castillo, a twenty-five-year-old Spanish woman, was killed by her doctors at her own…
The Mind’s Profane and Sacred Loves
The teachers you have make all the difference in your life. That they happened to come into…
